News Releases


New Treatment for Equine Endometritis Given USDA Approval

- SETTLE™ available to U.S. Equine Veterinarians in January, 2005 -

BELLEVILLE, ON, November 29, 2004 – Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has received approval from the U.S. Department of Agriculture (USDA) to market its proprietary product, SETTLE, for the treatment of equine endometritis caused by Streptococcus zooepidemicus. It is the Company’s intent to register this product in other jurisdictions as well.

“We are pleased to introduce this new therapy into the U.S. market in time for the 2005 equine breeding season,” said Martin Warmelink, President of Bioniche Animal Health, a Division of Bioniche Life Sciences Inc. “SETTLE has been clinically proven as a fast-acting, specific endometritis therapy for broodmares. It is the end result of clinical research conducted over a period of five breeding seasons.”

Endometritis is a non-life threatening disease that affects 25% to 40% of broodmares worldwide. The disease results in low conception rates or loss of pregnancies if conception occurs. It is a serious concern for breeders, often resulting in economic losses from low foaling rates, therapies, and repeated inseminations. If not successfully treated during the acute phase (conventional treatment involves intrauterine or intravenous antibiotics for three to four consecutive days), the original infection can result in a chronic, degenerative inflammatory condition compromising future fertility and requiring a laborious and costly battery of treatments. SETTLE offers breeders an additional therapy that can be easily assimilated into reproductive treatment protocols.

“SETTLE is an important product for Bioniche,” said Graeme McRae, President & CEO of Bioniche Life Sciences Inc. “It has been developed from one of our core proprietary technologies that has been shown in both humans and animals to induce a profound response in the immune system. Enhancing the body’s natural immune system to fight disease is preferable to introducing antibiotics and other pharmaceuticals. Excessive or inappropriate use of antibiotics can result in the proliferation of antibiotic-resistant bacteria.”

In August of this year, Bioniche released the first results of a fully controlled and monitored (GCP) study using a proprietary formulation of mycobacterial cell walls (SETTLE) to treat bacterial-induced endometritis in susceptible mares. The study results were presented at the Modern Vaccine/Adjuvant Formulation Conference in Prague, Czech Republic.

The study demonstrated that immunomodulation with a single dose of SETTLE resolved the bacterial infection and normalized the uterine inflammatory responses, resulting in successful treatment of the endometritis.

SETTLE will be officially unveiled at the upcoming Conference of the American Association of Equine Practitioners in Denver, Colorado, December 4th – 7th.

About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The Company employs more than 300 skilled personnel and has three principal operating divisions: Animal Health, Food Safety, and Human Health, which includes Bioniche Therapeutics and Bioniche Pharma Group. The Company’s primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. For more information, please visit

About Bioniche Animal Health
The Animal Health Division of Bioniche Life Sciences Inc. has marketing subsidiaries in Australia, Canada, Europe, and the United States. It is responsible for research, development, manufacturing, and marketing of veterinary biologics, pharmaceuticals, and nutritionals. This Division has a global portfolio of 60 products, which fall into the categories of: reproduction and embryo transfer; immunostimulant; and vaccines. Many of the innovative technologies discovered and developed by Bioniche Animal Health have been further developed by Bioniche Therapeutics (in the Human Health Division of Bioniche Life Sciences Inc.) into effective treatments for human health conditions.

Except for historical information, this news release may contain forward-looking statements that reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.

For further information, please contact:
Jennifer Shea
Corporate Communications Manager
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058 ext. 1250
Cell: (613) 331-6432

For SETTLE product information, please contact: Bioniche Animal Health USA, Inc.
Telephone: (888) 549-4503